Loading
A phase 1 trial of Vididencel run by University Medical Center Groningen, completed.
Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment is a phase 1 interventional study registered as NCT04739527 by University Medical Center Groningen, with 17 participants enrolled, started 2021-06-10. Conditions recorded: Ovarian Cancer. Interventions recorded: DCP-001.
Shares Vididencel, Mendus and the tag pipeline.
Shares Vididencel, Mendus and the tag pipeline.
Shares Vididencel, Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/